HIV-1 drug resistance: can we overcome?

被引：36

作者：

Brenner, BG ^{[1
]}

Turner, D ^{[1
]}

Wainberg, MA ^{[1
]}

机构：

[1] McGill Univ, Jewish Gen Hosp, AIDS Ctr, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2002年 / 2卷 / 07期

基金：

加拿大健康研究院;

关键词：

antiviral therapy; drug susceptibility; genotypic resistant variants; HIV-1 drug resistance; treatment interruption; viral fitness;

D O I：

10.1517/14712598.2.7.751

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Highly active antiretroviral therapy (HAART) targeting the viral reverse transcriptase and protease enzymes has advanced the treatment of HIV/AIDS. Nucleoside and non-nucleoside reverse transcriptase inhibitors and protease inhibitors used in combination can suppress viral replication thereby delaying disease progression. Emergence of HIV-1 mutated strains, resistant to one or more antiretroviral inhibitors or drug classes, remains one of the leading causes of treatment failure among patients living with HIV/AIDS. While advances in genotypic and phenotypic testing allow for drug resistance guided therapeutic management, the increasing prevalence of multi-drug resistance and an absence of new drug classes forewarn new problems in sustaining the effectiveness of HAART. One promising hope for continued benefit of antiretroviral therapy despite emergent resistance is the observed reduction in replicative ability or 'fitness' of multimutated viruses. This review discusses the development and influence of known drug mutations on drug susceptibility versus viral fitness.

引用

页码：751 / 761

页数：11

共 77 条

[1] Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy [J].

Albrecht, D ;

Zöllner, B ;

Feucht, HH ;

Lorenzen, T ;

Laufs, R ;

Stoehr, A ;

Plettenberg, A .

JOURNAL OF CLINICAL VIROLOGY, 2002, 24 (1-2) :93-98

[2] Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme [J].

Back, NKT ;

Nijhuis, M ;

Keulen, W ;

Boucher, CAB ;

Essink, BBO ;

vanKuilenburg, ABP ;

vanGennip, AH ;

Berkhout, B .

EMBO JOURNAL, 1996, 15 (15) :4040-4049

[3] A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy [J].

Baxter, JD ;

Mayers, DL ;

Wentworth, DN ;

Neaton, JD ;

Hoover, ML ;

Winters, MA ;

Mannheimer, SB ;

Thompson, MA ;

Abrams, DI ;

Brizz, BJ ;

Ioannidis, JPA ;

Merigan, TC .

AIDS, 2000, 14 (09) :F83-F93

[4] Diversity and complexity of HIV-1 drug resistance: A bioinformatics approach to predicting phenotype from genotype [J].

Beerenwinkel, N ;

Schmidt, B ;

Walter, H ;

Kaiser, R ;

Lengauer, T ;

Hoffmann, D ;

Korn, K ;

Selbig, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (12) :8271-8276

[5] Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1 [J].

Bleiber, G ;

Munoz, M ;

Ciuffi, A ;

Meylan, P ;

Telenti, A .

JOURNAL OF VIROLOGY, 2001, 75 (07) :3291-3300

[6] Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection [J].

Brenner, BG ;

Routy, JP ;

Petrella, M ;

Moisi, D ;

Oliveira, M ;

Detorio, M ;

Spira, B ;

Essabag, V ;

Conway, B ;

Lalonde, R ;

Sekaly, RP ;

Wainberg, MA .

JOURNAL OF VIROLOGY, 2002, 76 (04) :1753-1761

[7] Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection [J].

Call, SA ;

Saag, MS ;

Westfall, AO ;

Raper, JL ;

Pham, SV ;

Tolson, JM ;

Hellmann, NS ;

Cloud, GA ;

Johnson, VA .

JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (03) :401-408

[8]

Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1

[9]

Clevenbergh P, 2000, ANTIVIR THER, V5, P65

[10] HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].

COFFIN, JM .

SCIENCE, 1995, 267 (5197) :483-489

← 1 2 3 4 5 6 7 8 →